BNGO earnings analysis
What we found in BNGO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bionano delivered Q2 revenue of $8.171 million, beating the $7.476 million consensus estimate, while gross margin improved to 53.0% and consumables and flow-cell revenue grew 31% year over year. The company provided Q3 revenue guidance of $8.2 million-$8.6 million and full-year guidance of $31 million-$33 million, but EPS, operating margin, cash flow, and balance-sheet details are not present in the supplied 10-Q excerpt. Continued losses and the stated need for significant additional financing remain the principal risks, resulting in a neutral overall assessment.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat and Year-Over-Year Growth
- Q2 revenue was $8.171 million, exceeding the $7.476 million consensus estimate by $0.695 million and increasing from approximately $7 million in Q2 2025.
- Gross Margin Expanded
- Gross margin improved to 53.0% from 51.6% in Q2 2025, a 140-basis-point increase.
- Consumables and Flow Cells Accelerate
- Consumables and flow-cell revenue increased 31% year over year, indicating stronger recurring-product demand.
- Adjusted Operating Expense Decline
- Management reported that adjusted operating expenses declined, although the 10-Q excerpt does not provide the dollar amount or adjusted operating margin.
- Quantitative Revenue Outlook Provided
- The company issued Q3 2026 revenue guidance of $8.2 million-$8.6 million and full-year 2026 revenue guidance of $31 million-$33 million.
- Controls Remained Effective
- As of June 30, 2026, management concluded that disclosure controls were effective, and reported no material changes to internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- The company continues to operate at a loss; the related Q2 disclosure does not provide a reported EPS figure, while the consensus EPS estimate was negative $0.68. Continued losses could pressure liquidity and shareholder value.
- Additional Financing Required
- Management has stated that significant additional financing is required. The Q3 revenue outlook of $8.2 million-$8.6 million and full-year outlook of $31 million-$33 million may not be sufficient to eliminate financing dependence.
- Execution Risk Against Revenue Outlook
- The company must deliver full-year revenue of $31 million-$33 million after Q2 revenue of $8.171 million; failure to sustain growth in consumables and flow cells, which rose 31% year over year, could make the outlook difficult to achieve.
- No New Quantified Risk Update
- Item 1A of the 10-Q incorporates the risk factors from the December 31, 2025 Form 10-K and states that additional unknown risks may materially adversely affect the company; no new quantified risk-factor change is identified in the excerpt.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 53.0%
- Segment
- Consumables and flow cells: revenue increased 31% year over year; dollar revenue was not disclosed.
- Segment
- Other segment revenue: not disclosed.
What they said about what is next.
The 10-Q excerpt does not provide explicit EPS guidance or a prior outlook comparison. The related August 10, 2026 earnings release disclosed Q3 2026 revenue guidance of $8.2 million-$8.6 million and full-year 2026 revenue guidance of $31 million-$33 million; the release did not provide a prior outlook for comparison.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Bionano Genomics reported Q1 2026 revenue of $6.7 million, a 4% increase compared to $6.5 million in Q1 2025, though it recorded a larger net loss of $8.3 million, worsening from $3.1 million the previous year. The…
- 10-K · March 23, 2026
- Bionano describes a strategy of driving adoption of its optical genome mapping (OGM) platform across research and translational/clinical markets by selling instruments, consumables, VIA software, the Ionic® Purification…
- 10-Q · August 14, 2025
- Bionano reported Q2 revenue of $6,733,000 (down $1,038,000 or ~13.4% vs Q2 2024 $7,771,000) while GAAP net loss per share narrowed to $(1.99) from $(14.41) a year ago. Gross margin expanded to 51.6% and operating loss…
- 10-Q · November 8, 2023
- Bionano reported Q3 revenue of $9.318M, up from $7.221M a year ago, driven by increases in instruments, consumables and service revenues. The quarter contains a non-recurring goodwill impairment of $77.28M that drove…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BNGO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever